Canner David 4

What Happened

• David Canner, a director of Inhibikase Therapeutics, received a grant of 155,000 derivative shares (reported price $0.00) on 2026-06-26. The Form 4 lists this as an award/grant (transaction code A). The filing shows $0 reported value for the acquisition because this is a compensation award/derivative grant, not an open-market purchase.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-30.
• Transaction type: Award/Grant of derivative securities (A) — 155,000 shares; price reported $0.00.
• Vesting: Per footnote, the awards vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to continued service (Footnote F1).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Form 4 was filed on 2026-06-30 reporting the 6/26/2026 grant; no late-filing flag was indicated in the provided details.

Context

• This is a compensation-style award for a director that vests over time rather than an immediate cash purchase or sale. Such grants are common for board members and do not necessarily signal a buy/sell decision by the insider; the economic benefit depends on future vesting and the company's stock price at vesting.